Lv41
468 积分 2024-08-24 加入
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial
3小时前
待确认
Attention to the interactions between vincristine and triazole antifungals: perspectives from real-world retrospective analysis and pharmacovigilance assessment
23天前
已完结
In vitroandin vivopharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin
1个月前
已完结
Obstructive Hypertrophic Cardiomyopathy: A Review of New Therapies
1个月前
已完结
Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy
1个月前
已完结
Obstruction in Hypertrophic Cardiomyopathy: Many Faces
1个月前
已完结
Echocardiographic Drag Effect Index and Its Association with Response to Mavacamten in Obstructive Hypertrophic Cardiomyopathy
3个月前
已关闭
Physiologically based pharmacokinetic model of brivaracetam to predict the exposure and dose exploration in hepatic impairment and elderly populations
7个月前
已完结
Projections of Drug-Drug Interactions Caused by Time-Dependent Inhibitors of Cytochrome P450 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 Using In Vitro Data in Static and Dynamic Models
1年前
已完结
Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance
1年前
已完结
皖公网安备34019202002308
